Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/jRCTs032230528
jRCTs032230528RecruitingNot Applicable

Exploratory Research for Dexamethasone-Eluting Cochlear Implant Electrode (CIDEX)

Not provided0 sites1 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
1
Primary Endpoint
change in mean/median speech perception outcome as % correct of speech test in quiet (Japanese Monosyllable test: iCI2004)
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Single Arm Study
Intervention Model
Single Assignment
Primary Purpose
Treatment Purpose
Masking
Open(masking Not Used)

Eligibility Criteria

Ages
18age old over to No limit (—)
Sex
All

Inclusion Criteria

  • •General criteria
  • •(1) Patient agreed to participate in the study and signed to the informed consent document.
  • •(2) Age of 18 years or older when agreed.
  • •(3) General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study and realistic expectations, as deemed appropriate by the implanting surgeon.
  • •Medical criteria
  • •(1) Post-lingual hearing loss.
  • •(2) The pure tone average of affected side was below:
  • •Equal to 85dB HL or below at 125Hz
  • •Equal to 90dB HL or below at 250Hz
  • •Equal to 60dB HL or over at 2000Hz - 8000Hz
  • •(3) Evidence of functional auditory nerve in the ear to be implanted.
  • •(4) Subject report of having used an optimally fit hearing aids for a minimum of three months before deciding that a cochlear implant is the preferential option.
  • •(5) Cochlear anatomy compatible with the insertion of a FLEX28 electrode array.

Exclusion Criteria

  • •(1) Evidence of ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array or might cause an increased risk of infection (e.g., dysplastic cochlea), as confirmed by medical examination and/or as per CT/MRT (Computed Tomography/Magnetic Resonance Tomography).
  • •(2) Evidence of anatomic abnormalities that would prevent appropriate placement of the stimulator housing in the bone of the skull.
  • •(3) Known allergic reaction or intolerance to the materials used in the implant.
  • •(4) Known absence of cochlear development or if the cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway.
  • •(5) Evidence of active external or middle ear infection or history of recurrent middle ear infection in the ear to be implanted.
  • •(6) Evidence of perforated tympanic membrane in the ear to be implanted.
  • •(7) Patient reporting immunosuppressive therapy or corticosteroids therapy in the 4 weeks before enrolment.
  • •(8) Evidence of concomitant use of medicinal substances that could alter the therapeutic efficacy of dexamethasone.
  • •(9) Unwillingness or inability of the candidate to comply with all investigational requirements.
  • •(10) Evidence of medical contraindications to surgery of the middle and inner ear and anaesthesia.
  • •(11) Additional disabilities that would prevent or restrict participation in the audiological and medical evaluations required of the clinical investigation.

Outcomes

Primary Outcomes

change in mean/median speech perception outcome as % correct of speech test in quiet (Japanese Monosyllable test: iCI2004)

Time Frame: from prior to implantation to 7 months post-implantation

Clinical performance of the Mi1250 SYNCHRONY 2 FLEX28 DEX: change in mean/median speech perception outcome as % correct of speech test in quiet (Japanese Monosyllable test: iCI2004) from prior to implantation to 7 months post-implantation with the Mi1250 SYNCHRONY 2 FLEX28 DEX. *iCI2004 test: Nishio et al., Acta Otolaryngol. 2021;141(3):267-272.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Not provided

Similar Trials

Active, not recruiting
Phase 1
/AMedDRA version: 18.0Level: LLTClassification code 10000686Term: Acute bronchiolitisSystem Organ Class: 100000004862
EUCTR2015-002477-38-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Active, not recruiting
Phase 1
Iodine Contrasts Effectiveness and Safety in Contrast Enhanced Mammography and breast magnetic resonance imaging.MedDRA version: 20.0Level: PTClassification code: 10006187Term: Breast cancer Class: 100000004864Breast cancer
CTIS2023-507644-37-00niwersytet Jagiellonski Collegium Medicum900
Active, not recruiting
Phase 1
/AMedDRA version: 18.0Level: PTClassification code 10037377Term: Pulmonary embolismSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2014-001090-14-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)270
Active, not recruiting
Phase 1
SAFETY AND POTENTIAL EFFECT OF INNOVATIVE CELL-BASED THERAPY USING ADIPOSE-DERIVED STROMAL VASCULAR FRACTION IN PATIENTS WITH AUTOIMMUNE XEROSTOMIA (STUDY XEROCELL)AUTOIMMUNE XEROSTOMIA
CTIS2023-505149-20-00Assistance Publique Hopitaux De Marseille18
Active, not recruiting
Phase 1
DFabry diseaseMedDRA version: 20.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2018-000368-27-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE14